| Document |
Document Title |
|
WO/2023/005280A1 |
Disclosed in the present invention are preparation and application of an aminopyrimidine derivative selectively targeting CDK9. Also disclosed in the present invention are a preparation method for the compound and an application of the c...
|
|
WO/2023/286725A1 |
This UV absorber contains: at least one type of UV absorbing dye selected from a group consisting of compounds shown by general formulas (1)-(3); and a metal component containing at least one type of metal atom selected from the group co...
|
|
WO/2023/280684A1 |
A process for the synthesis of urea and melamine, wherein urea synthesized in a urea plant is used to produce melamine in a melamine plant connected to the urea plant, according to a high-pressure non-catalytic melamine synthesis process...
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/277289A1 |
The present application provides: a heterocyclic compound; and an organic light-emitting device which comprises an organic layer containing the heterocyclic compound.
|
|
WO/2022/270467A1 |
The purpose of the present invention is to provide a novel hydrazide compound. It is additionally the purpose of the present invention to provide: a curable resin composition that contains the hydrazide compound and that exhibits excepti...
|
|
WO/2022/267730A1 |
The present invention provides a method for synthesizing molecular glass, and the use thereof as a high-frequency low-dielectric-constant material. Specifically, the present invention provides a molecular glass monomer, which has a molec...
|
|
WO/2022/269532A1 |
The present invention relates to compounds of Formula (I) to their pharmaceutical composition and their use as a medicament, in particular for the treatment and/ or prevention of a tumour, viral infection, bacterial infection or neurodeg...
|
|
WO/2022/264827A1 |
A compound represented by formula (1).
|
|
WO/2022/260096A1 |
Provided is a photoelectric conversion element material that is for an imaging element and that contributes to production of a photoelectric conversion element that is for an imaging element and that exhibits excellent dark current and e...
|
|
WO/2022/253270A1 |
A substituted triazinylmethylcycloalkylcarboxylic acid derivative having a structure as shown in formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use...
|
|
WO/2022/252049A1 |
Provided are a light-emitting device and a preparation method therefor, and a display apparatus. By means of the light-emitting device, the problem of fluorescence quenching caused by the influence of an electron transport layer on a qua...
|
|
WO/2022/253599A1 |
The invention relates to an improved process for the manufacture of bis-resorcinyl triazines of formula (I), wherein R1 is hydrogen, C1-C18alkyl or C2-C18alkenyl and R2 is C1-C18alkyl or C2-C18alkenyl.
|
|
WO/2022/255428A1 |
The present invention addresses the problem of providing an aromatic compound which has excellent heat resistance, excellent solubility, and excellent electron-transporting properties and which gives thin films having excellent resistanc...
|
|
WO/2022/250339A1 |
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2022/239962A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/235771A1 |
Disclosed herein are methods of treating a disease or condition modulated by large-conductance potassium channels, the methods including administering, to a patient in need thereof, an effective amount of a large-conductance potassium ch...
|
|
WO/2022/225340A1 |
The present invention relates to: a compound for an organic optoelectronic element, wherein the compound is represented by chemical formula 1; a composition for an organic optoelectronic element, wherein the composition includes the comp...
|
|
WO/2022/213601A1 |
An organic light-emitting diode structure and a display apparatus are provided. A light-emitting layer, a hole blocking layer and an electron blocking layer in the organic light-emitting diode structure meet the following conditions: T1(...
|
|
WO/2022/215808A1 |
The present invention relates to a novel supramolecular self-assembly, a carbon nitride and a photocatalyst using same, and a manufacturing method therefor. The present invention can provide, by using a supermolecular self-assembly, a ca...
|
|
WO/2022/205090A1 |
A display substrate and a display apparatus. The display substrate comprises a driving circuit layer and a light-emitting structure layer which are arranged on a substrate in a stacking manner, wherein the light-emitting structure layer ...
|
|
WO/2022/194236A1 |
Provided herein is novel N-heterocyclic ketones that are useful for treatment of hypertrophic cardiomyopathy (HCM) and other heart diseases. The preparation method thereof, pharmaceutcal compositions comprising the compound.
|
|
WO/2022/190692A1 |
The present invention provides: a liquid crystal aligning agent which enables the formation of a liquid crystal alignment film that has high refractive index but does not have coloring properties, thereby having high light transmittance;...
|
|
WO/2022/191312A1 |
[Abstract] [Problem] To provide a method for producing a dealkoxyphenylation product with high yield from a substrate, e.g., a sugar, which is bonded to an alkoxyphenyl group through an oxygen atom. [Solution] A substrate that is bonded ...
|
|
WO/2022/184111A1 |
The present invention relates to the technical field of compounds. Disclosed are a plurality of small molecule compounds that are specifically bound to a tau protein and an application thereof. The chemical structures of these small mole...
|
|
WO/2022/172823A1 |
Provided is an additive for an electroplating solution, the additive containing a reaction product between at least one type of epoxy compound (a1) represented by general formula (1) and at least one type of tertiary amine compound (a2)....
|
|
WO/2022/173961A1 |
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.
|
|
WO/2022/166748A1 |
Provided in the present invention is a compound for treating or preventing vimentin-mediated diseases. The compound of the present invention is a s-triazine derivative, as shown in the following formula A, or a pharmaceutically acceptabl...
|
|
WO/2022/161801A1 |
The present invention relates to diaminotriazine compounds and to their use as herbicides. It also relates to agrochemical compositions for crop protection and to a method for controlling unwanted vegetation.
|
|
WO/2022/164835A1 |
Described herein are compositions and their use in methods and pharmaceutical compositions for inhibiting the binding between Yes-associated protein and TEA domain. Also, described herein are methods of using said compositions capable of...
|
|
WO/2022/161802A1 |
The present invention relates to diaminotriazine compounds and to their use as herbicides. It also relates to agrochemical compositions for crop protection and to a method for controlling unwanted vegetation.
|
|
WO/2022/152138A1 |
The present invention relates to a compound shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound for treating type II diabetes, prediabetes, obesity,...
|
|
WO/2022/147830A1 |
Provided are a method for preparing a polyisocyanate, a polyisocyanate obtained by using the method, and a reaction device used in the method. The method comprises the following steps: 1) subjecting a polyamine solution and a phosgene so...
|
|
WO/2022/138950A1 |
The present invention provides an organic electroluminescent element (1) including a light-emitting region (5) disposed between a negative electrode (4) and a positive electrode (3), a first positive-electrode-side organic layer (61), an...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/131887A1 |
The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
|
|
WO/2022/127518A1 |
Disclosed by the present application are a nitrogen-containing organic compound and an electronic component and electronic apparatus using same; the nitrogen-containing organic compound has an adamantyl-substituted nitrogen-containing he...
|
|
WO/2022/129139A1 |
The present invention relates to polyester polyols comprising units derived from a) at least one component (A) carrying at least one COOH group or a derivative thereof, wherein component (A) comprises (i) at least one compound carrying t...
|
|
WO/2022/123216A1 |
The application relates to a method for the flow synthesis manufacture of RDX, comprising the steps of preparing input flow reagent A, comprising hexamine dissolved in nitric acid with a concentration less than 92%, preparing input flow ...
|
|
WO/2022/124827A1 |
The present invention relates to a novel compound having excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device having improved characteristics in terms of luminescenc...
|
|
WO/2022/105852A1 |
Provided are a triazine dione derivative, a preparation method therefor and an application thereof in medicine. Specifically, provided are a triazine dione derivative represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2022/103031A1 |
Provided is a triazine or pyrimidine derivative that contributes to a substantial improvement in lifespan of an organic electroluminescent element by effectively absorbing high energy in the UV range from an external light source to mini...
|
|
WO/2022/102992A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2022/100194A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an organic electroluminescent device, and an electronic device. The nitrogen-containing compound is shown as formul...
|
|
WO/2022/095756A1 |
The present invention relates to a compound as shown in formula (I) serving as a mutant isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) inhibitor, a preparation method therefor and a pharmaceutical composition thereof. The present inventi...
|
|
WO/2022/088911A1 |
The present invention relates to a benzophenanthrene derivative and an application thereof. The structural formula of the benzophenanthrene derivative is represented by formula (I). The benzophenanthrene derivative set forth in the prese...
|
|
WO/2022/091091A1 |
The present invention relates to polymers comprising bifunctional mono- or polycyclic heterocyclic or heteroaromatic repeating units having disinfecting activity, compositions thereof, and methods for disinfecting surfaces utilizing said...
|
|
WO/2022/087350A1 |
Highly porous nucleophilic organic cages (Nu-POC) were in-situ synthesized on cotton fibers by a condensation reaction between cyanuric chloride and melamine, and the products were employed as a robust wearable and flexible detoxifying p...
|
|
WO/2022/075219A1 |
The purpose of the present invention is to provide a triazine compound that contributes in manufacturing of an organic electroluminescent element having excellent durability and drive voltage.　This triazine compound is represented by f...
|
|
WO/2022/076628A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
